Global prevalence of metabolic syndrome in patients with gout: A systematic review and meta-analysis.

Background

Evidence increasingly supports the association of gout with metabolic syndrome (MetS). Studies have indicated that the prevalence of MetS among patients with gout ranges from 17 to over 70 percent. Aim: The purpose of this study was to establish the global prevalence of MetS in patients diagnosed with gout.

Methods

To obtain studies related to the title, we systematically searched PubMed, Scopus, Web of Science, Embase, Science-Direct, and Google Scholar search engine to find all relevant articles that were published until the end of November 2023. Obtain and carry out the necessary evaluations. The I2 index was used to examine the heterogeneity of studies and the Random Effects model was used to analyze the data.

Results

Following evaluation, we discovered 19 studies (23 findings), revealing an overall prevalence of MetS in gout patients as 46.8% (95% CI: 38.6-55.2%). On a regional level, subgroup analysis indicated the highest prevalence of MetS was in the American continent, with a rate of 60.6% (95% CI: 44.8-74.5%). In terms of the tool used for MetS measurement, the subgroup analysis showed the maximum prevalence rate of 54.6% was associated with the International Diabetes Federation criteria tool.

Conclusion

The results of this research showed that MetS is common among gout patients; therefore, policymakers should reduce the consequences and costs of this condition by focusing on these patients and performing appropriate and timely treatment and training.